X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs MERCK LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA MERCK LTD TORRENT PHARMA/
MERCK LTD
 
P/E (TTM) x 36.9 48.9 75.4% View Chart
P/BV x 5.7 6.4 89.4% View Chart
Dividend Yield % 0.9 0.4 215.4%  

Financials

 TORRENT PHARMA   MERCK LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
MERCK LTD
Dec-16
TORRENT PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1,7681,060 166.8%   
Low Rs1,186623 190.3%   
Sales per share (Unadj.) Rs346.1632.4 54.7%  
Earnings per share (Unadj.) Rs55.245.7 120.7%  
Cash flow per share (Unadj.) Rs73.362.3 117.6%  
Dividends per share (Unadj.) Rs14.0011.00 127.3%  
Dividend yield (eoy) %0.91.3 72.5%  
Book value per share (Unadj.) Rs257.1388.8 66.1%  
Shares outstanding (eoy) m169.2216.60 1,019.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.31.3 320.7%   
Avg P/E ratio x26.818.4 145.4%  
P/CF ratio (eoy) x20.113.5 149.2%  
Price / Book Value ratio x5.72.2 265.4%  
Dividend payout %25.424.1 105.5%   
Avg Mkt Cap Rs m249,88713,969 1,788.9%   
No. of employees `00011.81.6 744.2%   
Total wages/salary Rs m9,9341,487 668.2%   
Avg. sales/employee Rs Th4,971.56,631.9 75.0%   
Avg. wages/employee Rs Th843.2939.2 89.8%   
Avg. net profit/employee Rs Th792.4479.4 165.3%   
INCOME DATA
Net Sales Rs m58,56910,498 557.9%  
Other income Rs m2,233242 921.2%   
Total revenues Rs m60,80210,741 566.1%   
Gross profit Rs m13,7731,135 1,213.1%  
Depreciation Rs m3,069276 1,114.0%   
Interest Rs m2,0560-   
Profit before tax Rs m10,8811,102 987.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545343 450.1%   
Profit after tax Rs m9,336759 1,230.2%  
Gross profit margin %23.510.8 217.4%  
Effective tax rate %14.231.1 45.6%   
Net profit margin %15.97.2 220.5%  
BALANCE SHEET DATA
Current assets Rs m53,8416,410 840.0%   
Current liabilities Rs m31,6128,828 358.1%   
Net working cap to sales %38.0-23.0 -164.7%  
Current ratio x1.70.7 234.6%  
Inventory Days Days9758 168.5%  
Debtors Days Days8438 218.2%  
Net fixed assets Rs m42,0791,406 2,992.0%   
Share capital Rs m846166 509.8%   
"Free" reserves Rs m42,6556,286 678.6%   
Net worth Rs m43,5016,455 674.0%   
Long term debt Rs m22,4080-   
Total assets Rs m101,2508,828 1,146.9%  
Interest coverage x6.3NM-  
Debt to equity ratio x0.50-  
Sales to assets ratio x0.61.2 48.6%   
Return on assets %11.38.6 130.9%  
Return on equity %21.511.8 182.5%  
Return on capital %19.617.1 114.9%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m20,066959 2,092.9%   
Fx outflow Rs m5,3042,612 203.1%   
Net fx Rs m14,762-1,653 -893.0%   
CASH FLOW
From Operations Rs m10,1271,070 946.1%  
From Investments Rs m-7,869-750 1,049.6%  
From Financial Activity Rs m-1,918-150 1,280.4%  
Net Cashflow Rs m212171 123.8%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 7.0 18.2 38.6%  
FIIs % 12.6 1.0 1,260.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 29.1 30.2%  
Shareholders   26,511 28,591 92.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   FULFORD INDIA  ALKEM LABORATORIES  DIVIS LABORATORIES  SANOFI INDIA  ALEMBIC PHARMA  

Compare TORRENT PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jun 21, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS